MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..10 of 16 - per page Next page
Order by
These hybrid antibody molecules can be engineered with a variety of small synthetic molecules, and the combination of immunogenic properties results in compounds with powerful target destruction or imaging capabilities. More
A cancer therapy and diagnostic that utilizes a variation of "Boron Neutron Capture Therapy" to deliver intense, short-lived, therapeutic doses of radiation specifically to active tumor sites. More
Identification and characterization of three (3) novel fully human monoclonal antibodies, which may be used to prevent binding of IGF-I to its concomitant receptor IGFIR, consequently, modulating diseases such as cancer. More
NGR peptides for targeting therapeutic and diagnostic agents to cancer cells More
Compositions and methods of use for delivering therapeutic agents transported on or inside nanostructures to target sites for cancer therapy More
This new technology is designed to screen for the autoantibodies for a spectrum of secreted tumor antigens in a single assay. More
An anti-mesothelin antibody of human origin has been generated; it has the ability to efficiently recognize mesothelin on the surface of cells, and induce ADCC in mesothelin-positive cells. More
Two anti-CD22 antibodies of human origin have been generated; each has the ability to recognize CD22 on the surface of Raji cells. More
This technology describes several antibodies, both polyclonal and monoclonal, to the prolactin receptor. More
Compositions and methods which employ a combination of monoclonal antibodies which bind to HGF and prevent it from binding to its receptor met in a manner that HGF/met signaling is neutralized More
Displaying 1..10 of 16 - per page Next page
Order by

Clients in focus...

Get the Flash Player to see this rotator.

Partnering and licensing intelligence in life sciences industry
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us